The startup develops a tumor in situ target capture technology platform that enhances in vivo drug target screening, significantly increasing the success rate of drug target discovery. This approach addresses the limitations of traditional in vitro systems, enabling the development of more effective tumor treatments at a lower cost for patients.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional in vitro drug screening methods often fail to accurately replicate the complex tumor microenvironment, leading to high failure rates in drug target discovery and subsequent clinical trials. This discrepancy between in vitro results and in vivo efficacy increases the cost and time required to develop effective cancer treatments.
Solution
The startup offers a tumor in situ target capture technology platform designed to enhance in vivo drug target screening. This platform enables researchers to identify and validate drug targets directly within the tumor microenvironment, providing a more accurate representation of drug-target interactions. By capturing targets in their native context, the technology improves the success rate of drug target discovery, leading to the development of more effective and targeted tumor treatments. This approach reduces the reliance on traditional in vitro systems, which often fail to translate into successful in vivo outcomes.
Target Audience
The primary audience includes pharmaceutical companies, biotechnology firms, and academic research institutions involved in drug discovery and development for cancer therapeutics.
Features
- In situ target capture technology for direct analysis within the tumor microenvironment
- Enhanced in vivo drug target screening capabilities
- Improved accuracy in identifying and validating relevant drug targets
- Reduced reliance on traditional in vitro methods